meta|Evidence - COVID-19
click on circles to display study description...
face mask (n=-9) vs. control (n=-9)
randomized controlled trial risk of bias NA
mask
no mask
preventing respiratory virus transmission
Influenza virus
China (Hong Kong)
Cluster randomized trial
Cluster randomized trial
face mask (n=-9) vs. control (n=-9)
cluster randomized trial risk of bias NA
face mask /- hand hygiene
control
3 arms : face mask (n=378), face mask hand hygiene (n=367), control (n=552)
preventing respiratory virus transmission
open-label, randomized
USA
face mask (n=52) vs. control (n=53)
cluster randomized trial risk of bias NA
mask
control
preventing respiratory virus transmission
open-label, randomized
france, multicentric (3)
face mask (n=-9) vs. control (n=-9)
randomized controlled trial risk of bias NA
surgical masks or non-fit-tested P2 masks
no masks
preventing respiratory virus transmission
face mask (n=-9) vs. control (n=-9)
cluster randomized trial risk of bias NA
Medical Mask, N95 Fit tested, N95 non-fit tested
no mask
preventing respiratory virus transmission
Respiratory virus
15 Beijing hospitals
Cluster randomized trial
Cluster randomized trial
face mask (n=123) vs. control (n=122)
cluster randomized trial risk of bias NA
medical maskused by sick individuals with influenza-like illness
control
preventing respiratory virus transmission
face mask (n=1623) vs. control (n=1642)
cluster randomized trial risk of bias NA
mask or/and hand hygiene
participants were asked to wear their masks for at least six hours per day while in their residence hall adn encouraged to wear it outside
no mask
3 arms study : mask (n=1623), mask hand hygiene (n=1839), control (=1642)
preventing respiratory virus transmission
Influenza virus
randomized
USA, multicentric (37)
Cluster randomized trial
Cluster randomized trial
face mask (n=-9) vs. control (n=-9)
cluster randomized trial risk of bias NA
paper surgical face masks
control
preventing respiratory virus transmission
face mask (n=26) vs. control (n=30)
cluster randomized trial risk of bias NA
Mask
no mask
preventing respiratory virus transmission
Influenza virus
Germany
Cluster randomized trial
Cluster randomized trial
face mask (n=-9) vs. control (n=-9)
cluster randomized trial risk of bias NA
use of 50 surgical facemasks worn over five days
no facemasks
preventing respiratory virus transmission
face mask (n=-9) vs. control (n=-9)
randomized controlled trial risk of bias NA
Mask
no mask
preventing respiratory virus transmission
Respiratory virus
Australia
Cluster randomized trial
Cluster randomized trial
face mask (n=-9) vs. control (n=-9)
cluster randomized trial risk of bias NA
mask
control
preventing respiratory virus transmission
favipiravir (n=36) vs. standard of care (n=19)
randomized controlled trial some concerns about risk of bias
favipiravir
ffavipiravir was 1600 mg (bid) on the first day, and 600 mg (bid) from the 2nd day to the 7th day, orally
standard of care
preventing respiratory virus transmission
Open-label.
Multicenter, China
powered by vis.js Network